Cargando…
A commentary of “Type I interferon deficiency can lead to severe COVID-19” in 10 remarkable discoveries from 2020 in Nature
In two articles published in Science online in September 2020, Zhang et al. [1] and Bastard et al. [2] elucidated a key factor in the progression to severe COVID-19; namely, a deficiency in interferon, especially type I interferon (IFN I). This deficiency might be caused by diverse reasons such as g...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Publishing Services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801063/ http://dx.doi.org/10.1016/j.fmre.2022.01.005 |
_version_ | 1784642373358190592 |
---|---|
author | Fang, Xiangming |
author_facet | Fang, Xiangming |
author_sort | Fang, Xiangming |
collection | PubMed |
description | In two articles published in Science online in September 2020, Zhang et al. [1] and Bastard et al. [2] elucidated a key factor in the progression to severe COVID-19; namely, a deficiency in interferon, especially type I interferon (IFN I). This deficiency might be caused by diverse reasons such as genetic mutations of genes encoding key antiviral signaling molecules, or the ‘neutralization’ of IFN I by endogenous antibodies. How does IFN I deficiency cause severe, life-threatening COVID-19? The most straightforward explanation is that such deficiency allows uncontrolled virus replication and spread. IFN I deficiency may also have other impacts on immune system function. Individuals with mutations in the IFN-I-induced signaling pathways may benefit from interferon therapies. In addition, individuals with neutralizing antibodies against IFN-α and IFN-ω may also benefit from other types of interferons provided in the therapy, such as IFN-β and IFN-λ. |
format | Online Article Text |
id | pubmed-8801063 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Authors. Publishing Services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88010632022-01-31 A commentary of “Type I interferon deficiency can lead to severe COVID-19” in 10 remarkable discoveries from 2020 in Nature Fang, Xiangming Fundamental Research Commentary In two articles published in Science online in September 2020, Zhang et al. [1] and Bastard et al. [2] elucidated a key factor in the progression to severe COVID-19; namely, a deficiency in interferon, especially type I interferon (IFN I). This deficiency might be caused by diverse reasons such as genetic mutations of genes encoding key antiviral signaling molecules, or the ‘neutralization’ of IFN I by endogenous antibodies. How does IFN I deficiency cause severe, life-threatening COVID-19? The most straightforward explanation is that such deficiency allows uncontrolled virus replication and spread. IFN I deficiency may also have other impacts on immune system function. Individuals with mutations in the IFN-I-induced signaling pathways may benefit from interferon therapies. In addition, individuals with neutralizing antibodies against IFN-α and IFN-ω may also benefit from other types of interferons provided in the therapy, such as IFN-β and IFN-λ. The Authors. Publishing Services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. 2022-03 2022-01-30 /pmc/articles/PMC8801063/ http://dx.doi.org/10.1016/j.fmre.2022.01.005 Text en © 2022 The Authors. Publishing Services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Commentary Fang, Xiangming A commentary of “Type I interferon deficiency can lead to severe COVID-19” in 10 remarkable discoveries from 2020 in Nature |
title | A commentary of “Type I interferon deficiency can lead to severe COVID-19” in 10 remarkable discoveries from 2020 in Nature |
title_full | A commentary of “Type I interferon deficiency can lead to severe COVID-19” in 10 remarkable discoveries from 2020 in Nature |
title_fullStr | A commentary of “Type I interferon deficiency can lead to severe COVID-19” in 10 remarkable discoveries from 2020 in Nature |
title_full_unstemmed | A commentary of “Type I interferon deficiency can lead to severe COVID-19” in 10 remarkable discoveries from 2020 in Nature |
title_short | A commentary of “Type I interferon deficiency can lead to severe COVID-19” in 10 remarkable discoveries from 2020 in Nature |
title_sort | commentary of “type i interferon deficiency can lead to severe covid-19” in 10 remarkable discoveries from 2020 in nature |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801063/ http://dx.doi.org/10.1016/j.fmre.2022.01.005 |
work_keys_str_mv | AT fangxiangming acommentaryoftypeiinterferondeficiencycanleadtoseverecovid19in10remarkablediscoveriesfrom2020innature AT fangxiangming commentaryoftypeiinterferondeficiencycanleadtoseverecovid19in10remarkablediscoveriesfrom2020innature |